Cynata Therapeutics Limited (CYYNF)
| Previous Close | 0.1100 |
| Open | 0.1100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1100 - 0.1100 |
| 52 Week Range | 0.0720 - 0.2400 |
| Volume | |
| Avg. Volume | 3 |
| Market Cap | 24.606M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
- PR Newswire
First Patient Treated in Phase 2 GvHD Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
- PR Newswire
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU), up to the 10-week follow-up time point.
